Welcome to our dedicated page for DiaMedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
DiaMedica Therapeutics Inc. (DMAC) – Form 4 insider transaction: On 07/23/2025, 10% owner and director Jan Stahlberg, through his wholly-owned entity Trill AB, purchased 1,542,857 common shares of DMAC at $3.50 per share (Code “P”).
Following the buy, Stahlberg’s indirect holding via Trill AB rose to 6,764,465 shares. No derivative securities were reported. The filing signals a sizeable capital outlay of roughly $5.4 million, lifting the insider’s stake and reinforcing alignment with public shareholders.